原发性乳腺浸润性导管癌组织中生长抑素受体表达及其预后价值

Prognostic value of the somatostatin receptor expression in human primary breast invasive ductal carcinoma

目的:研究原发性乳腺浸润性导管癌(HPB IDC)患者肿瘤组织中生长抑素受体(SSTR)的表达情况、肿瘤病理分化程度和病理分期以及与生存的关系,为临床根据肿瘤组织中SSTR表达判断病情、预后及指导治疗提供理论依据。方法:应用免疫组化法(IHC)检测82例HPB IDC患者肿瘤组织中SSTR的表达,分析这些患者肿瘤组织SSTR、病理分期和分化程度与生存的关系,探讨HPB IDC肿瘤组织中SSTR的表达与预后的关系。结果:HPB IDC肿瘤组织SSTR表达阴性、弱阳性、中度阳性和强阳性的患者5年累积总生存率(OS)分别为59.1%、76.2%、85.2%和100.0%;病理分级为高分化、中分化和低分化的患者5年累积OS分别为94.1%、90.6%和60.0%;根据肿瘤(T)、结节(N)及转移(M)情况进行分类的癌症分类法(TNM)分期,Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期的患者5年累积OS分别为100.0%、86.0%、56.3%和25.0%。结论:HPB IDC肿瘤组织中SSTR的表达与乳腺癌患者的预后显著相关。

Objective： To investigate the relationship of the expression of the somatostatin receptor （SSTR） with tumor stages, tumor differentiation and the survival time in patients with human primary breast invasive duetal carcinoma （HPBIDC） and to provide theoretical evidence for the diagnosis, prognosis and treatment of the disease based on the SSTR expression. Methods： We detected the SSTR expression in the tumor tissues of 82 HPBIDC patients, and analyzed the relationship of the SSTR expression with the prognosis and survival time of the patients. Results： In the HPBIDC patients, the 5-year overall survival （OS） rates of the negative, weakly positive, moderately positive and strongly positive SSTR expression groups were 59.1, 76.2, 85.2 and 100.0% , those of the well, moderately and poorly differentiated groups were 94.1, 90.6 and 60.0% , and those of the TNM Ⅰ , TNM Ⅱ , TNM Ⅲ and TNM Ⅳ groups were 100.0, 86.0, 56.3 and 25.0% , respectively. Conclusion ： The expression of SSTR is significantly correlated with the prognosis of human primary breast invasive ductal carcinoma.